Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Catalyst selects new drug candidate for hemophilia program
CB 813 is designed to substantially enhance clot-generating activity at the site of bleeding and therefore achieve clinical efficacy with fewer and lower doses than current therapy. In
CB 813 is designed to substantially enhance clot-generating activity at the site of bleeding and therefore achieve clinical efficacy with fewer and lower doses than current therapy. In
JVHL is located in Allen Park, Michigan and the agreement is renewable after the first year. Paul Valenstein, president of Joint Venture Hospital Laboratories (JVHL), said: “This partnership
Mr Lieb has selected these antibodies for use in his work that is part of the National Human Genome Research Institute’s model-organism Encode (modENCODE) project. The project is
The Phase II study is a two-arm, randomized, controlled 100-patient trial of first-line treatment of metastatic colorectal cancer. The objective of the Phase II trial is to compare
NB S101, a dual acting bone agent, has a demonstrated ability to decrease resorption of bone while maintaining formation of new bone. The drug has been formulated as
Dr Tellier joins MacroGenics after a 20 year career in commercial development at Novartis. Since February 2007, he served as chairman and CEO of Novartis Pharma France and
The Contrave clinical development program includes four Phase III clinical trials evaluating a variety of obesity and metabolic-related outcome measures. Orexigen previously announced that enrollment was completed in
ClariVein is a percutaneous, 2 2/3 Fr (0.035″) catheter, containing a rotating wire driven by a motor, that enhances fluid dispersion in the treatment area. John Marano, co-founder,
The Dilon system is a high-resolution gamma camera that enables molecular imaging of the breast and other small organs for early cancer detection. Robert Moussa, chairman and CEO
The company intends to close on approximately $1.5 million immediately upon AMEX approval and customary closing conditions, with the balance at the company’s option and subject to stockholder